VYNE Stock Analysis: Buy, Sell, or Hold?
VYNE - VYNE Therapeutics Inc. Common Stock
$0.66
0.01 (1.82%)
▲
5d:
+4.57%
30d:
-1.43%
90d:
+9.46%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When VYNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VYNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VYNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VYNE is currently trading at $0.66, which is considered fair relative to its 30-day fair value range of $0.65 to $0.68.
Technical Outlook: Technically, VYNE is in a strong uptrend. Immediate support is located at $0.62, while resistance sits at $0.69.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+207.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VYNE is in a strong uptrend. Immediate support is located at $0.62, while resistance sits at $0.69.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+207.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.65 -
$0.68
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 207.7% below Wall St target ($2.00)
Trading Range Analysis
30-Day Trading Range
$0.65 -
$0.68
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$0.69
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.39
Wall Street Target
$2.00
(+207.7%)
Revenue Growth (YoY)
-57.4%
Share & Embed Analysis
Last updated: June 24, 2026 3:28 PM ET
Data refreshes hourly during market hours. Next update: 4:28 PM
Data refreshes hourly during market hours. Next update: 4:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |
